LIFE – Successful in-vitro quality testing of sensor

Bergen, Norway, June 13th, 2024: Today, Lifecare ASA (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces that the company has concluded a successful in-vitro quality test of sensor for use in longevity study.

Reference is made to stock exchange notification June 10th, 2024. The internal in-vitro quality test has been successfully conducted.